Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Schizophrenia and major depressive disorder (MDD) are associated with increased risks of immunologic disease and metabolic syndrome. It is unclear to what extent growth, immune or glucose dysregulations are similarly present in these disorders without the influence of treatment or chronicity. OBJECTIVE: To conduct a meta-analysis investigating whether there are altered peripheral growth, immune or glucose metabolism compounds in drug-naïve first-episode patients with schizophrenia or MDD compared with controls. DATA SOURCES AND STUDY SELECTION: Case-control studies reporting compound measures in drug-naïve first-episode patients with schizophrenia or MDD compared with controls in the Embase, PubMed and PsycINFO databases. DATA EXTRACTION AND SYNTHESIS: Two independent authors extracted data for a random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Peripheral growth, immune or glucose metabolism compounds in schizophrenia or MDD compared with controls. Standardized mean differences were quantified with Hedges' g (g). RESULTS: 74 studies were retrieved comprising 3453 drug-naïve first-episode schizophrenia patients and 4152 controls, and 29 studies were retrieved comprising 1095 drug-naïve first-episode MDD patients and 1399 controls. Growth factors: brain-derived neurotrophic factor (BDNF) (g = -0.77, P < .001) and nerve growth factor (NGF) (g = -2.51, P = .03) were decreased in schizophrenia. For MDD, we observed a trend toward decreased BDNF (g = -0.47, P = .19) and NGF (g = -0.33, P = .08) levels, and elevated vascular endothelial growth factor levels (g = 0.40, P = .03). Immune factors: interleukin (IL)-6 (g = 0.95, P < .001), IL-8 (g = 0.59, P = .001) and tumor necrosis factor alpha (TNFα) (g = 0.48, P = .002) were elevated in schizophrenia. For C-reactive protein (CRP) (g = 0.57, P = .09), IL-4 (g = 0.44, P = .10) and interferon gamma (g = 0.33, P = .11) we observed a trend toward elevated levels in schizophrenia. In MDD, IL-6 (g = 0.62, P = .007), TNFα (g = 1.21, P < .001), CRP (g = 0.53, P < .001), IL-1β (g = 1.52, P = .009) and IL-2 (g = 4.41, P = .04) were elevated, whereas IL-8 (g = -0.84, P = .01) was decreased. The fasting glucose metabolism factors glucose (g = 0.24, P = .003) and insulin (g = 0.38, P = .003) were elevated in schizophrenia. CONCLUSIONS AND RELEVANCE: Both schizophrenia and MDD show alterations in growth and immune factors from disease onset. An altered glucose metabolism seems to be present from onset in schizophrenia. These findings support efforts for further research into transdiagnostic preventive strategies and augmentation therapy for those with immune or metabolic dysfunctions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) · Nature Genetics · doi:10.1038/ng.2711 · Cited by 2,263
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Depression and Type 2 Diabetes Over the Lifespan
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008) · Diabetes Care · doi:10.2337/dc08-0985 · Cited by 1,558
Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies
Köhler, C. A., Freitas, T. H., Maes, M., de Andrade, N. Q., Liu, C. S., Fernandes, B. S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12698 · Cited by 1,443
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Brown, A. S., & Derkits, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030361 · Cited by 1,269
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1332 · Cited by 846
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702
Self-citationLamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
Self-citationInflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Brites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599
Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study
Benros, M. E., Waltoft, B. L., Nordentoft, M., Østergaard, S. D., Eaton, W. W., Krogh, J., & Mortensen, P. B. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1111 · Cited by 572
Benraiss, A., Chmielnicki, E., Lerner, K., Roh, D., & Goldman, S. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06718.2001 · Cited by 540
Association of Schizophrenia and Autoimmune Diseases: Linkage of Danish National Registers
Eaton, W. W., Byrne, M., Ewald, H., Mors, O., Chen, C.-Y., Agerbo, E., & Mortensen, P. B. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.521 · Cited by 527
Cytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Dupilumab: A review of its use in the treatment of atopic dermatitis
Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.022 · Cited by 343
Association of high-sensitivity C-reactive protein with de novo major depression
Pasco, J. A., Nicholson, G. C., Williams, L. J., Jacka, F. N., Henry, M. J., Kotowicz, M. A., Schneider, H. G., Leonard, B. E., & Berk, M. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076430 · Cited by 321
Autoimmune diseases, bipolar disorder, and non-affective psychosis
Eaton, W. W., Pedersen, M. G., Nielsen, P. R., & Mortensen, P. B. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00853.x · Cited by 262
Perkins, D. O., Jeffries, C. D., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Seidman, L. J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu099 · Cited by 238
Genetic Contributions of Inflammation to Depression
Barnes, J., Mondelli, V., & Pariante, C. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.169 · Cited by 237
Pillinger, T., D’Ambrosio, E., McCutcheon, R., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0058-9 · Cited by 230 · cited 1×
“Additionally, we compared the effect sizes statistically of each compound between schizophrenia and MDD using a Wald-type test (Pillinger et al., 2019).”
MethodKöhler-Forsberg, O., Petersen, L., Gasse, C., Mortensen, P. B., Dalsgaard, S., Yolken, R. H., Mors, O., & Benros, M. E. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3428 · Cited by 215
Pillinger, T., Osimo, E. F., Brugger, S., Mondelli, V., McCutcheon, R. A., & Howes, O. D. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby160 · Cited by 190
Takao, K., Kobayashi, K., Hagihara, H., Ohira, K., Shoji, H., Hattori, S., Koshimizu, H., Umemori, J., Toyama, K., Nakamura, H. K., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.38 · Cited by 173
Chew, L.-J., Fusar-Poli, P., & Schmitz, T. (2013) · Developmental Neuroscience · doi:10.1159/000346157 · Cited by 154
Osimo, E. F., Cardinal, R. N., Jones, P. B., & Khandaker, G. M. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.031 · Cited by 124
Chen, G., Guo, Y., Zhu, H., Kuang, W., Bi, F., Ai, H., Gu, Z., Huang, X., Lui, S., & Gong, Q. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.011 · Cited by 81
Immune and Neuroimmune Alterations in Mood Disorders and Schizophrenia
Drexhage, R. C., Weigelt, K., van Beveren, N., Cohen, D., Versnel, M. A., Nolen, W. A., & Drexhage, H. A. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-387718-5.00007-9 · Cited by 71
Cited by
The role of adipokines in health and disease
Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023) · Biomedicines · doi:10.3390/biomedicines11051290 · Cited by 463
Cavaleri, D., Moretti, F., Bartoccetti, A., Mauro, S., Crocamo, C., Carrà, G., & Bartoli, F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105159 · Cited by 146
The Role of Cytokines in the Pathogenesis of Schizophrenia
Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173849 · Cited by 102
“showed reduced levels of IL-4 in FEAN patients [14], three other meta-analyses, including two based on much larger samples, showed its unaltered levels compared to HCs [13,16,37].”
BackgroundResultInfluentialDawidowski, B., Grelecki, G., Biłgorajski, A., Podwalski, P., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010232 · Cited by 22
“One of the important common features of IL-1β, IL-6, IFN-γ and TNF-α is their effect on hematopoiesis, in particular stimulation of the differentiation, maturation, and proliferation of cells of the myeloid lineage, which includes neutrophils, and not lymphoid lineage [40].”
BackgroundInfluentialSmit, A. J. T., Wu, G. W. Y., Rampersaud, R., Reus, V. I., Wolkowitz, O. M., & Mellon, S. H. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107045 · Cited by 9
“A recent meta-analysis exclusively including studies with drug-naïve, first episode MDD participants, failed to find significantly decreased BDNF in MDD (Çakici et al., 2020).”
Metadata
- Authors
- Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., Dalm, V. A., de Haan, L., & van Beveren, N. J. M.
- Venue
- Brain, Behavior, and Immunity
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 88
- Pages
- 547-558
- ISSN
- 0889-1591 (ISSN-L)
- OpenAlex
- W3018397877
- Cited by
- 160
- References
- 33
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.